Evidence map›Paper›PMID 24878961›Full record

ArticleThe Journal of biological chemistry2014

A cell-penetrating antibody fragment against HIV-1 Rev has high antiviral activity: characterization of the paratope.

Xiaolei Zhuang, Stephen J Stahl, Norman R Watts, Michael A DiMattia, Alasdair C Steven, Paul T Wingfield

Open access · hybridAbstract read
In one paragraph

Article in The Journal of biological chemistry, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
1.5field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 20 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Review
  6. Review
  7. Review
  8. Article
  9. Review
  10. Review
  11. Cell-Permeable Peptides Containing Cycloalanine Residues.Angewandte Chemie (International ed. in English) · 2016
    Article
  12. Article
  13. Review
  14. Article
  15. The Antimicrobial and Antiviral Applications of Cell-Penetrating Peptides.Methods in molecular biology (Clifton, N.J.) · 2015
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Xiaolei ZhuangFrom the Protein Expression Laboratory and.
Stephen J StahlFrom the Protein Expression Laboratory and.
Norman R WattsFrom the Protein Expression Laboratory and.
Michael A DiMattiathe Laboratory of Structural Biology Research, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, Maryland 20892.
Alasdair C Steventhe Laboratory of Structural Biology Research, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, Maryland 20892.
Paul T WingfieldFrom the Protein Expression Laboratory and pelpw@helix.nih.gov.
Protein Express (United States) · US

Funding

Production Of HIV And HIV Related Proteins For Structural StudiesZIAAR041115 · NIAMS · NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES · PI WINGFIELD, PAUL T · 2009 to 2025
$16.9M
Structural Biology Of Retrovirus AssemblyZIAAR041166 · NIAMS · NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES · PI STEVEN, ALASDAIR C. · 2009 to 2020
$9.2M
Intramural NIH HHSNIAID NIH HHS HHSN272200700041C
6 · The paper itself

Abstract

The HIV-1 protein Rev oligomerizes on viral transcripts and directs their nuclear export. Previously, a Fab against Rev generated by phage display was used to crystallize and solve the structure of the Rev oligomerization domain. Here we have investigated the capability of this Fab to block Rev oligomerization and inhibit HIV-1 replication. The Fab itself did not have antiviral activity, but when a Tat-derived cell-penetrating peptide was appended, the resulting molecule (FabRev1-Tat) was strongly inhibitory of three different CCR5-tropic HIV-1 isolates (IC50 = 0.09-0.44 μg/ml), as assessed by suppression of reverse transcriptase activity in infected peripheral blood mononuclear cells, and had low cell toxicity (TC50 > 100 μg/ml). FabRev1-Tat was taken up by both peripheral blood mononuclear and HEK293T cells, appearing in both the cytoplasm and nucleus, as shown by immunofluorescence confocal laser scanning microscopy. Computational alanine scanning was used to identify key residues in the complementarity-determining regions to guide mutagenesis experiments. Residues in the light chain CDR3 (LCDR3) were assessed to be important. Residues in LCDR3 were mutated, and LCDR3-Tyr(92) was found to be critical for binding to Rev, as judged by surface plasmon resonance and electron microscopy. Peptides corresponding to all six CDR regions were synthesized and tested for Rev binding. None of the linear peptides had significant affinity for Rev, but four of the amide-cyclic forms did. Especially cyclic-LCDR3 (LGGYPAASYRTA) had high affinity for Rev and was able to effectively depolymerize Rev filaments, as shown by both surface plasmon resonance and electron microscopy.

Indexed as

Amino Acid SequenceAnti-HIV AgentsBinding Sites, AntibodyCell-Penetrating PeptidesComplementarity Determining RegionsHEK293 CellsHIV-1HumansImmunoglobulin Fab FragmentsKineticsMicroscopy, Electron, TransmissionModels, MolecularMolecular Sequence DataMutagenesis, Site-DirectedProtein BindingProtein EngineeringAnti-HIV AgentsCell-Penetrating PeptidesComplementarity Determining RegionsImmunoglobulin Fab Fragmentsrev Gene Products, Human Immunodeficiency Virusrev protein, Human Immunodeficiency Virus-1AIDSCell-penetrating peptide (CPP)Cyclic PeptideMonoclonal AntibodyPhage Display

Identifiers

PMID24878961
PMCPMC4106338
OpenAlexW1990210813

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.